GlaxoSmithKline offers Merck up to €3.7bn to form immunotherapy venture

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 13:28

GlaxoSmithKline agreed to offer Merck up to €3.7bn (£3.2bn) to form a partnership to develop an immonutherapy for the treatment of cancer.

The deal involved GSK making an upfront payment to Merck of €300m regarding the treatment, known as M7824.

The German group would also be eligible for potential development milestone payments of up to €500m triggered by data from an M7824 lung cancer programme.

Merck would then be eligible for further payments upon successfully achieving future approval and commercial milestones of up to €2.9bn.

Eight related immuno-oncology clinical development studies were either ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers.

'Despite recent medical advances, many patients with difficult-to-treat cancers don't currently benefit from immuno-oncology therapies leaving them with limited treatment options,' GSK chief scientific officer Hal Barron said.

'M7824 brings together two different biological functions in a single molecule and we have observed encouraging clinical results in treating certain cancer patients, particularly those people with non-small cell lung cancer.'

'I'm excited by the potential impact this first-in-class immunotherapy could have on the lives of cancer patients.'

At 1:28pm: (LON:GSK) GlaxoSmithKline PLC share price was +19.9p at 1499.9p

Related content

Smiths Group and Pharmaceutical Stocks

“Having enjoyed a strong finish on Thursday amid a big slide in sterling, the FTSE 100 is modestly lower on Friday as news that the...

Fri, 22/03/2019 - 10:04

Kingfisher in a fix as DIY expert looks for a new boss

Kingfisher’s failure to increase its dividend for a tenth year in a row – and join an elite club of just 26 current FTSE...

Wed, 20/03/2019 - 15:47

Broker Forecast - Shore Capital issues a broker note on GlaxoSmithKline PLC

Shore Capital today downgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from buy).

Broker Forecasts data provided by

Fri, 08/03/2019 - 08:50

GlaxoSmithKline's JV ViiV Healthcare says trials for injectable HIV treatment met objectives

GlaxoSmithKline said Friday its ViiV Healthcare joint venture with Pfizer had said two clinical trials of a an injectable two-drug regime for the treatment of...

Fri, 08/03/2019 - 07:31

How I invest: hoping for good returns in retirement

Peter from Bromley has been investing in the stock market since the 1980s when he bought shares in British Gas. Now aged 71, the former...

Thu, 07/03/2019 - 00:00